Onivyde 4.3 mg/mL (Irinotecan Hydrochloride INJECTION, POWDER, FOR SOLUTION) 4.3 mg/mL

Onivyde 4.3 mg/mL is an injectable powder for solution, used for specific medical treatments. This formulation by Ipsen Biopharmaceuticals is designed for intravenous administration.

Strength

4.3 mg/mL

Pack Size

1 VIAL, SINGLE-DOSE in 1 CARTON (15054-0043-1) / 10 mL in 1 VIAL, SINGLE-DOSE

Manufacturer / TM Owner

Ipsen Biopharmaceuticals, Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Onivyde 4.3 mg/mL is primarily used in combination with other medications for the treatment of advanced cancers. It is often prescribed for patients who have previously undergone other treatments. The active ingredient, irinotecan hydrochloride, is a chemotherapy agent that works by interfering with the growth of cancer cells.

Side Effects

Common effects of Onivyde 4.3 mg/mL may include nausea, vomiting, diarrhea, and fatigue. Some patients may experience more severe side effects, such as low blood cell counts or infections. It is important to discuss any unusual symptoms with a healthcare provider.

Precautions & Warnings

Onivyde 4.3 mg/mL should be handled with care, as it is a potent medication. It is essential to follow the prescribed dosage and administration instructions provided by a healthcare professional. Patients should be monitored regularly for any adverse reactions.

Avoid Interactions

Onivyde 4.3 mg/mL may interact with other medications, including those that affect the liver or bone marrow. It is important to inform healthcare providers about all medications being taken to avoid potential interactions. Alcohol and certain foods may also affect the efficacy of the treatment.

Frequently Asked Questions

Onivyde 4.3 mg/mL is used in combination with other drugs to treat advanced cancers in patients who have previously undergone other treatments.

Onivyde 4.3 mg/mL is administered intravenously as an injection after being prepared from the powder for solution.

Common side effects may include nausea, vomiting, diarrhea, and fatigue. Severe side effects can include low blood cell counts or infections.

Onivyde 4.3 mg/mL may interact with other medications, so it is important to consult a healthcare provider before combining it with other drugs.

Patients should follow the prescribed dosage and administration instructions carefully and be monitored regularly for any adverse reactions.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.